Inhibikase Therapeutics Inc (NASDAQ:IKT) — Market Cap & Net Worth
Market Cap & Net Worth: Inhibikase Therapeutics Inc (IKT)
Inhibikase Therapeutics Inc (NASDAQ:IKT) has a market capitalization of $119.23 Million ($119.23 Million) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #18518 globally and #4094 in its home market, demonstrating a -1.04% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Inhibikase Therapeutics Inc's stock price $1.91 by its total outstanding shares 74516635 (74.52 Million). Analyse Inhibikase Therapeutics Inc cash flow conversion to see how efficiently the company converts income to cash.
Inhibikase Therapeutics Inc Market Cap History: 2020 to 2026
Inhibikase Therapeutics Inc's market capitalization history from 2020 to 2026. Data shows change from $3.08 Billion to $142.33 Million (-47.36% CAGR).
Index Memberships
Inhibikase Therapeutics Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.00% | #519 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #1799 of 3165 |
Weight: Inhibikase Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Inhibikase Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Inhibikase Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
363.29x
Inhibikase Therapeutics Inc's market cap is 363.29 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $3.08 Billion | $698.47K | -$2.88 Million | 4416.79x | N/A |
| 2021 | $657.24 Million | $3.10 Million | -$14.81 Million | 211.97x | N/A |
| 2022 | $223.55 Million | $123.44K | -$17.91 Million | 1811.00x | N/A |
| 2023 | $94.64 Million | $260.50K | -$19.03 Million | 363.29x | N/A |
Competitor Companies of IKT by Market Capitalization
Companies near Inhibikase Therapeutics Inc in the global market cap rankings as of May 4, 2026.
Key companies related to Inhibikase Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Inhibikase Therapeutics Inc Historical Marketcap From 2020 to 2026
Between 2020 and today, Inhibikase Therapeutics Inc's market cap moved from $3.08 Billion to $ 142.33 Million, with a yearly change of -47.36%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $142.33 Million | -6.83% |
| 2025 | $152.76 Million | -36.92% |
| 2024 | $242.18 Million | +155.91% |
| 2023 | $94.64 Million | -57.67% |
| 2022 | $223.55 Million | -65.99% |
| 2021 | $657.24 Million | -78.70% |
| 2020 | $3.08 Billion | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Inhibikase Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $119.23 Million USD |
| MoneyControl | $119.23 Million USD |
| MarketWatch | $119.23 Million USD |
| marketcap.company | $119.23 Million USD |
| Reuters | $119.23 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Inhibikase Therapeutics Inc
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a p… Read more